Viking Therapeutics

VKTX

Market cap $3.4B

VK2735 is being developed in both subcutaneous and oral forms, and upcoming Phase 1 maintenance trial results are a major catalyst. VK2735 may offer efficacy advantages over competitors' oral drugs.

Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.18, denoting a +1.64% move from the preceding trading day.

Viking Therapeutics (VKTX) is the most closely watched biotech acquisition target. A buyer such as Eli Lilly (LLY) would benefit, as would Viking shareholders, and at least one GLP-1 competitor.

The weight loss opportunity is a significant one for companies and investors -- and companies involved have seen their shares soar. Analysts predict the market will reach almost $100 billion within a few years.

Enthusiasm for Viking Therapeutics and its weight-loss candidate has come and gone, and for good reason. While Viking is still trying to bring its first candidate to market, rivals are already increasing the competition with new product launches.

Big pharma still needs additional late-stage obesity drug assets. Viking's obesity pipeline could attract major pharmaceutical acquisition interest.

Eli Lilly dominates the weight loss drug market and competes with fellow pharma giant Novo Nordisk. Viking is studying promising weight loss candidates in late-stage trials.

SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference in June. Details of the company's participation are as follows: William Blair 46th Annual Growth Stock Conference Details: Viking management will deliver a corporate presentation, followed by a breakout session, and participate in investor meetings.Conference Dates: June 2-4, 2026Presentation Date/Time: Tuesday, June 2nd at 2:00 pm – 2:30 pm CTBreakout session: Tuesday, June 2nd at 2:40 pm – 3:10 pm CTLocation: Chicago, IL Jefferies Global Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings.

Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not be the best investment option for you in 2026.